Development of an Anthrax Vaccine

炭疽疫苗的开发

• 批准号: 7696717
• 金额: $ 1307.29万
• 依托单位: EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-25 至 2011-09-24
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7696717
• 关键词: Development; Anthrax; Vaccine; Development; Anthrax; Vaccine

This contract supports the advanced development of an immuno-enhanced version of the licensed anthrax vaccine through cGMP manufacturing and has an option for a Phase 1 clinical trial. The candidate vaccine will be formulated with an immunostimulant to minimize the amount of vaccine and time required to attain protective immunity.

该合同支持通过CGMP制造的许可炭疽疫苗的免疫增强版本的高级开发，并可以选择1期临床试验。候选疫苗将使用免疫刺激剂制定，以最大程度地减少获得保护性免疫所需的疫苗和时间。